Search details
1.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35405088
2.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Article
in English
| MEDLINE | ID: mdl-32780421
3.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30632020
4.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28664507
5.
Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer.
EClinicalMedicine
; 55: 101756, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36457648
6.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res
; 29(4): 805-814, 2023 02 16.
Article
in English
| MEDLINE | ID: mdl-36441798
7.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Breast Care (Basel)
; 16(1): 50-58, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33716632
8.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
J Clin Oncol
; 37(10): 799-808, 2019 04 01.
Article
in English
| MEDLINE | ID: mdl-30785826
Results
1 -
8
de 8
1
Next >
>>